Skin cancer and Parkinson's disease
Identifieur interne : 001A05 ( Main/Exploration ); précédent : 001A04; suivant : 001A06Skin cancer and Parkinson's disease
Auteurs : Joaquim J. Ferreira [Portugal] ; Dulce Neutel [Portugal] ; Tiago Mestre [Portugal] ; Miguel Coelho [Portugal] ; Mário M. Rosa [Portugal] ; Olivier Rascol [France] ; Cristina Sampaio [Portugal]Source :
- Movement Disorders [ 0885-3185 ] ; 2010-01-30.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
- Antiparkinson Agents (administration & dosage), Antiparkinson Agents (adverse effects), Breast Neoplasms (epidemiology), Breast Neoplasms (etiology), Female, Humans, Malignant melanoma, Malignant tumor, Melanoma (chemically induced), Melanoma (epidemiology), Melanoma (etiology), Nervous system diseases, Parkinson Disease (complications), Parkinson Disease (drug therapy), Parkinson Disease (epidemiology), Parkinson disease, Parkinson's disease, Risk Factors, Skin, Skin Neoplasms (chemically induced), Skin Neoplasms (epidemiology), Skin Neoplasms (etiology), Skin cancer, Skin disease, Thyroid Neoplasms (epidemiology), Thyroid Neoplasms (etiology), cancer, melanoma, skin.
- MESH :
- chemical , administration & dosage : Antiparkinson Agents.
- chemical , adverse effects : Antiparkinson Agents.
- chemically induced : Melanoma, Skin Neoplasms.
- complications : Parkinson Disease.
- drug therapy : Parkinson Disease.
- epidemiology : Breast Neoplasms, Melanoma, Parkinson Disease, Skin Neoplasms, Thyroid Neoplasms.
- etiology : Breast Neoplasms, Melanoma, Skin Neoplasms, Thyroid Neoplasms.
- Female, Humans, Risk Factors.
Abstract
The report of an increased frequency of melanoma during the clinical development of rasagiline prompted a renewed interest in a possible association between skin cancer and Parkinson's disease (PD). The evaluation of this risk ended in a recommendation to perform a periodic dermatological examination as a follow‐up measure of their treatment. The recognition of this safety concern lead to the need to clarify if the risk of skin cancer is indeed associated with PD and if levodopa or other anti‐parkinsonian drugs might contribute to increase such risk. To answer these questions, we critically reviewed all clinical studies available concerning the association between skin cancer and PD. We found 26 studies on cancer occurrence in PD. The best data available suggest the risk of cancer is reduced in PD patients. However, specific cancers like thyroid and the female breast were reported at higher‐than‐expected rates. Additionally, it was suggested that PD patients have a higher frequency of melanoma and non‐melanoma skin cancers than the general population. The data on non‐melanoma skin cancer are less robust than the data on melanoma. Causal factors remain unknown. Due to the weak association between skin cancer and PD, no robust recommendation can be made regarding the need for periodic dermatological screening. © 2010 Movement Disorder Society
Url:
DOI: 10.1002/mds.22855
Affiliations:
- France, Portugal
- Midi-Pyrénées
- Toulouse
- Université Toulouse III - Paul Sabatier, Université de Toulouse
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000490
- to stream Istex, to step Curation: 000490
- to stream Istex, to step Checkpoint: 000684
- to stream PubMed, to step Corpus: 001A42
- to stream PubMed, to step Curation: 001A42
- to stream PubMed, to step Checkpoint: 001611
- to stream Ncbi, to step Merge: 002960
- to stream Ncbi, to step Curation: 002960
- to stream Ncbi, to step Checkpoint: 002960
- to stream Main, to step Merge: 001E41
- to stream PascalFrancis, to step Corpus: 000A86
- to stream PascalFrancis, to step Curation: 002233
- to stream PascalFrancis, to step Checkpoint: 000836
- to stream Main, to step Merge: 002423
- to stream Main, to step Curation: 001A05
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Skin cancer and Parkinson's disease</title>
<author><name sortKey="Ferreira, Joaquim J" sort="Ferreira, Joaquim J" uniqKey="Ferreira J" first="Joaquim J." last="Ferreira">Joaquim J. Ferreira</name>
</author>
<author><name sortKey="Neutel, Dulce" sort="Neutel, Dulce" uniqKey="Neutel D" first="Dulce" last="Neutel">Dulce Neutel</name>
</author>
<author><name sortKey="Mestre, Tiago" sort="Mestre, Tiago" uniqKey="Mestre T" first="Tiago" last="Mestre">Tiago Mestre</name>
</author>
<author><name sortKey="Coelho, Miguel" sort="Coelho, Miguel" uniqKey="Coelho M" first="Miguel" last="Coelho">Miguel Coelho</name>
</author>
<author><name sortKey="Rosa, Mario M" sort="Rosa, Mario M" uniqKey="Rosa M" first="Mário M." last="Rosa">Mário M. Rosa</name>
</author>
<author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name>
<affiliation><country>France</country>
<placeName><settlement type="city">Toulouse</settlement>
<region type="region" nuts="2">Midi-Pyrénées</region>
</placeName>
<orgName type="university" n="3">Université Toulouse III - Paul Sabatier</orgName>
<orgName type="institution" wicri:auto="newGroup">Université de Toulouse</orgName>
</affiliation>
</author>
<author><name sortKey="Sampaio, Cristina" sort="Sampaio, Cristina" uniqKey="Sampaio C" first="Cristina" last="Sampaio">Cristina Sampaio</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:E07B15D78830DC683FDBACB04F513F13EB3845E3</idno>
<date when="2010" year="2010">2010</date>
<idno type="doi">10.1002/mds.22855</idno>
<idno type="url">https://api.istex.fr/document/E07B15D78830DC683FDBACB04F513F13EB3845E3/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000490</idno>
<idno type="wicri:Area/Istex/Curation">000490</idno>
<idno type="wicri:Area/Istex/Checkpoint">000684</idno>
<idno type="wicri:doubleKey">0885-3185:2010:Ferreira J:skin:cancer:and</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:20063399</idno>
<idno type="wicri:Area/PubMed/Corpus">001A42</idno>
<idno type="wicri:Area/PubMed/Curation">001A42</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001611</idno>
<idno type="wicri:Area/Ncbi/Merge">002960</idno>
<idno type="wicri:Area/Ncbi/Curation">002960</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">002960</idno>
<idno type="wicri:Area/Main/Merge">001E41</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:10-0303300</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000A86</idno>
<idno type="wicri:Area/PascalFrancis/Curation">002233</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000836</idno>
<idno type="wicri:doubleKey">0885-3185:2010:Ferreira J:skin:cancer:and</idno>
<idno type="wicri:Area/Main/Merge">002423</idno>
<idno type="wicri:Area/Main/Curation">001A05</idno>
<idno type="wicri:Area/Main/Exploration">001A05</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Skin cancer and Parkinson's disease</title>
<author><name sortKey="Ferreira, Joaquim J" sort="Ferreira, Joaquim J" uniqKey="Ferreira J" first="Joaquim J." last="Ferreira">Joaquim J. Ferreira</name>
<affiliation wicri:level="1"><country xml:lang="fr">Portugal</country>
<wicri:regionArea>Neurological Clinic Research Unit, Institute of Molecular Medicine, Lisbon School of Medicine, Lisbon</wicri:regionArea>
<wicri:noRegion>Lisbon</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Neutel, Dulce" sort="Neutel, Dulce" uniqKey="Neutel D" first="Dulce" last="Neutel">Dulce Neutel</name>
<affiliation wicri:level="1"><country xml:lang="fr">Portugal</country>
<wicri:regionArea>Neurological Clinic Research Unit, Institute of Molecular Medicine, Lisbon School of Medicine, Lisbon</wicri:regionArea>
<wicri:noRegion>Lisbon</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Mestre, Tiago" sort="Mestre, Tiago" uniqKey="Mestre T" first="Tiago" last="Mestre">Tiago Mestre</name>
<affiliation wicri:level="1"><country xml:lang="fr">Portugal</country>
<wicri:regionArea>Neurological Clinic Research Unit, Institute of Molecular Medicine, Lisbon School of Medicine, Lisbon</wicri:regionArea>
<wicri:noRegion>Lisbon</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Coelho, Miguel" sort="Coelho, Miguel" uniqKey="Coelho M" first="Miguel" last="Coelho">Miguel Coelho</name>
<affiliation wicri:level="1"><country xml:lang="fr">Portugal</country>
<wicri:regionArea>Neurological Clinic Research Unit, Institute of Molecular Medicine, Lisbon School of Medicine, Lisbon</wicri:regionArea>
<wicri:noRegion>Lisbon</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Rosa, Mario M" sort="Rosa, Mario M" uniqKey="Rosa M" first="Mário M." last="Rosa">Mário M. Rosa</name>
<affiliation wicri:level="1"><country xml:lang="fr">Portugal</country>
<wicri:regionArea>Neurological Clinic Research Unit, Institute of Molecular Medicine, Lisbon School of Medicine, Lisbon</wicri:regionArea>
<wicri:noRegion>Lisbon</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name>
<affiliation wicri:level="1"><country xml:lang="fr">France</country>
<wicri:regionArea>Departments of Clinical Pharmacology and Neurosciences, INSERM CIC‐9302 and UMR‐825, University Hospital, Toulouse</wicri:regionArea>
<placeName><settlement type="city">Toulouse</settlement>
</placeName>
<placeName><settlement type="city">Toulouse</settlement>
<region type="region" nuts="2">Midi-Pyrénées</region>
</placeName>
<orgName type="university" n="3">Université Toulouse III - Paul Sabatier</orgName>
<orgName type="institution" wicri:auto="newGroup">Université de Toulouse</orgName>
</affiliation>
</author>
<author><name sortKey="Sampaio, Cristina" sort="Sampaio, Cristina" uniqKey="Sampaio C" first="Cristina" last="Sampaio">Cristina Sampaio</name>
<affiliation wicri:level="1"><country xml:lang="fr">Portugal</country>
<wicri:regionArea>Neurological Clinic Research Unit, Institute of Molecular Medicine, Lisbon School of Medicine, Lisbon</wicri:regionArea>
<wicri:noRegion>Lisbon</wicri:noRegion>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2010-01-30">2010-01-30</date>
<biblScope unit="vol">25</biblScope>
<biblScope unit="issue">2</biblScope>
<biblScope unit="page" from="139">139</biblScope>
<biblScope unit="page" to="148">148</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">E07B15D78830DC683FDBACB04F513F13EB3845E3</idno>
<idno type="DOI">10.1002/mds.22855</idno>
<idno type="ArticleID">MDS22855</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiparkinson Agents (administration & dosage)</term>
<term>Antiparkinson Agents (adverse effects)</term>
<term>Breast Neoplasms (epidemiology)</term>
<term>Breast Neoplasms (etiology)</term>
<term>Female</term>
<term>Humans</term>
<term>Malignant melanoma</term>
<term>Malignant tumor</term>
<term>Melanoma (chemically induced)</term>
<term>Melanoma (epidemiology)</term>
<term>Melanoma (etiology)</term>
<term>Nervous system diseases</term>
<term>Parkinson Disease (complications)</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson Disease (epidemiology)</term>
<term>Parkinson disease</term>
<term>Parkinson's disease</term>
<term>Risk Factors</term>
<term>Skin</term>
<term>Skin Neoplasms (chemically induced)</term>
<term>Skin Neoplasms (epidemiology)</term>
<term>Skin Neoplasms (etiology)</term>
<term>Skin cancer</term>
<term>Skin disease</term>
<term>Thyroid Neoplasms (epidemiology)</term>
<term>Thyroid Neoplasms (etiology)</term>
<term>cancer</term>
<term>melanoma</term>
<term>skin</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antiparkinson Agents</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term>
</keywords>
<keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Melanoma</term>
<term>Skin Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Breast Neoplasms</term>
<term>Melanoma</term>
<term>Parkinson Disease</term>
<term>Skin Neoplasms</term>
<term>Thyroid Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Breast Neoplasms</term>
<term>Melanoma</term>
<term>Skin Neoplasms</term>
<term>Thyroid Neoplasms</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Female</term>
<term>Humans</term>
<term>Risk Factors</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Cancer de la peau</term>
<term>Maladie de Parkinson</term>
<term>Mélanome malin</term>
<term>Pathologie de la peau</term>
<term>Pathologie du système nerveux</term>
<term>Peau</term>
<term>Tumeur maligne</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The report of an increased frequency of melanoma during the clinical development of rasagiline prompted a renewed interest in a possible association between skin cancer and Parkinson's disease (PD). The evaluation of this risk ended in a recommendation to perform a periodic dermatological examination as a follow‐up measure of their treatment. The recognition of this safety concern lead to the need to clarify if the risk of skin cancer is indeed associated with PD and if levodopa or other anti‐parkinsonian drugs might contribute to increase such risk. To answer these questions, we critically reviewed all clinical studies available concerning the association between skin cancer and PD. We found 26 studies on cancer occurrence in PD. The best data available suggest the risk of cancer is reduced in PD patients. However, specific cancers like thyroid and the female breast were reported at higher‐than‐expected rates. Additionally, it was suggested that PD patients have a higher frequency of melanoma and non‐melanoma skin cancers than the general population. The data on non‐melanoma skin cancer are less robust than the data on melanoma. Causal factors remain unknown. Due to the weak association between skin cancer and PD, no robust recommendation can be made regarding the need for periodic dermatological screening. © 2010 Movement Disorder Society</div>
</front>
</TEI>
<affiliations><list><country><li>France</li>
<li>Portugal</li>
</country>
<region><li>Midi-Pyrénées</li>
</region>
<settlement><li>Toulouse</li>
</settlement>
<orgName><li>Université Toulouse III - Paul Sabatier</li>
<li>Université de Toulouse</li>
</orgName>
</list>
<tree><country name="Portugal"><noRegion><name sortKey="Ferreira, Joaquim J" sort="Ferreira, Joaquim J" uniqKey="Ferreira J" first="Joaquim J." last="Ferreira">Joaquim J. Ferreira</name>
</noRegion>
<name sortKey="Coelho, Miguel" sort="Coelho, Miguel" uniqKey="Coelho M" first="Miguel" last="Coelho">Miguel Coelho</name>
<name sortKey="Mestre, Tiago" sort="Mestre, Tiago" uniqKey="Mestre T" first="Tiago" last="Mestre">Tiago Mestre</name>
<name sortKey="Neutel, Dulce" sort="Neutel, Dulce" uniqKey="Neutel D" first="Dulce" last="Neutel">Dulce Neutel</name>
<name sortKey="Rosa, Mario M" sort="Rosa, Mario M" uniqKey="Rosa M" first="Mário M." last="Rosa">Mário M. Rosa</name>
<name sortKey="Sampaio, Cristina" sort="Sampaio, Cristina" uniqKey="Sampaio C" first="Cristina" last="Sampaio">Cristina Sampaio</name>
</country>
<country name="France"><noRegion><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001A05 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001A05 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= Main |étape= Exploration |type= RBID |clé= ISTEX:E07B15D78830DC683FDBACB04F513F13EB3845E3 |texte= Skin cancer and Parkinson's disease }}
This area was generated with Dilib version V0.6.23. |